Abstract
The effectiveness of KRAS G12C inhibition as a cancer treatment was recently reported. Knowing the association between RAS mutation and the expression level of immune checkpoint markers is of interest since it may guide a potential combination therapy of RAS inhibition and immune checkpoint blockade.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
